Although not official and largely anecdotal, there are early signs that Gilead Sciences’ experimental antiviral drug remdesivir is effective in treating COVID-19.
Shares of Gilead Sciences Inc. rose 10 percent after a report that patients with COVID-19 treated with the company’s experimental drug, remdesivir, in a clinical trial showed rapid recovery in fever and respiratory symptoms.
Gilead Sciences Inc.’s shares surged 16 percent in after-hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug remdesivir in severe COVID-19 patients.
A new survey conducted by Fingerpaint – a full-service health and wellness marketing agency – about the use of telemedicine shows that a majority (76%) of healthcare practitioners (HCPs) agree it is convenient for their patient, but most (64%) think it is not as effective as engaging with their patient in an office.
A drug used to treat head lice in humans and parasites in animals demonstrated efficacy against COVID-19 in laboratory tests, and the U.S. Food and Drug Administration is already warning people to not attempt to self-medicate with the drug to treat the novel coronavirus.
Sir Andrew Witty – the former head of GlaxoSmithKline, current president of UnitedHealth Group and chief executive officer of Optum – is temporarily stepping away from his duties to co-lead a World Health Organization effort to combat COVID-19.
Social distancing has become the new norm in the attempt to prevent the spread of COVID-19, and that norm could become a mainstay of life for the next couple years, a new study suggests.
A trial in China testing Gilead Sciences Inc.’s antiviral drug remdesivir in those with mild symptoms of COVID-19 was suspended due to a lack of eligible patients, according to a website maintained by the U.S. government.
French healthcare company Sanofi and U.S. start-up technology company Luminostics said they were joining up to work on developing a smartphone-based self-testing solution to see if someone has the COVID-19 coronavirus.
Biogen Inc. joined a consortium to build a collection of biological and medical data, where the company’s employees who had tested for and recovered from the coronavirus would be able to participate.
